News and Media

Boston Biomedical is headquartered in Cambridge, Massachusetts, and is engaged in the discovery and development of novel therapeutics targeting cancer stem cell pathways. A list of recent press releases and other news from Boston Biomedical can be found below. To contact our media relations staff, please click here.

  • All
  • Press Releases
  • In the Media
  • News
07/10/17

Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Myelodysplastic Syndrome

CAMBRIDGE, Mass., July 10, 2017 /PRNewswire/ -- Boston Biomedical, Inc., an industry leader in the development of next-generation cancer therapeutics, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for DSP-7888, an investigational cancer peptide vaccine, for the treatment of myelodysplastic syndrome (MDS). MDS is a group of rare blood disorders characterized by abnormal development of blood cells within the bone marrow.1  Read More

06/30/17

Boston Biomedical Presents Data for Investigational Cancer Stemness Inhibitor Napabucasin in Metastatic Colorectal and Pancreatic Cancer at ESMO GI 2017

Boston Biomedical, Inc., an industry leader in the development of next-generation cancer therapeutics designed to inhibit cancer stemness pathways, featured two oral and two poster presentations evaluating napabucasin in metastatic colorectal cancer (mCRC) and pancreatic adenocarcinoma (mPDAC) at the European Society of Medical Oncology (ESMO) 19th World Congress on Gastrointestinal Cancer, held from June 28 to July 1 in Barcelona, Spain. Napabucasin is an orally-administered investigational agent designed to inhibit cancer stemness pathways by targeting STAT3. The abstracts were simultaneously published in the ESMO GI 2017 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology. Read More

06/26/17

Boston Biomedical Announces Unblinding of the Phase 3 Trial in Patients with Advanced Gastric/GEJ Cancer

Boston Biomedical, Inc., today announced that the BRIGHTER Trial evaluating the efficacy and safety of napabucasin plus paclitaxel versus paclitaxel alone for patients with advanced gastric/GEJ (gastroesophageal junction) cancer will be unblinded. This decision is based on a recommendation by the trial's Data and Safety Monitoring Board (DSMB), following a pre-specified interim analysis on two-thirds of the total planned events. The DSMB determined that the study was unlikely to reach its primary endpoint of superior overall survival for napabucasin plus paclitaxel versus paclitaxel alone. No safety concerns were identified by the DSMB. Boston Biomedical has accepted this recommendation to unblind the study and plans to continue to follow all endpoints as defined in the protocol. Boston Biomedical will communicate further details to investigators shortly. Read More

06/12/17

Boston Biomedical, Inc. Chief Executive Officer Patricia S. Andrews Appointed to Board of Directors of GlycoMimetics

Boston Biomedical, Inc. Chief Executive Officer Patricia S. Andrews has been appointed to the board of directors of GlycoMimetics, Inc. (NASDAQ: GLYC). This appointment reflects Ms. Andrews’ position as an industry leader in the oncology field and the value of her extensive commercial experience, leading multiple companies through the transition from R&D to commercial-stage, and successfully launching first-in-class oncology products. Her contributions at leading oncology-focused companies – Boston Biomedical, Inc., Incyte and Pfizer – have been instrumental in building a high performing organization and preparation for the successful commercialization of the company’s assets. Read More

06/05/17

Boston Biomedical Presents Data for Investigational Stemness Inhibitor Amcasertib at ASCO 2017

CAMBRIDGE, Mass., June 5, 2017 /PRNewswire/ -- Boston Biomedical, Inc., an industry leader in the development of next-generation cancer therapeutics designed to inhibit cancer stemness pathways, will present data today from a phase 1b/2 study evaluating amcasertib monotherapy in two solid tumor subpopulations – advanced adenoid cystic carcinoma (ACC) and advanced head and neck cancers – at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Amcasertib is an orally-administered investigational agent designed to inhibit cancer stemness pathways, including Nanog, by targeting stemness kinases. Read More

06/03/17

Boston Biomedical Presents Data Suggesting Anti-Cancer Activity of Investigational Stemness Inhibitor Napabucasin in Seven Tumor Types at ASCO 2017

Boston Biomedical, Inc., an industry leader in the development of next-generation cancer therapeutics designed to inhibit cancer stemness pathways, will present phase 1b/2 clinical data evaluating napabucasin, an orally-administered investigational agent designed to inhibit cancer stemness pathways by targeting STAT3, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Presented today and tomorrow (June 4), these study results show anti-cancer activity in advanced or metastatic disease in seven tumor types: colorectal cancer (mCRC), pancreatic cancer (mPDAC), non-squamous non-small cell lung cancer, ovarian cancer, breast cancer, hepatocellular cancer, and melanoma. Read More

05/18/17

Boston Biomedical Announces Presentations for Investigational First-in-Class Cancer Stemness Inhibitors Napabucasin and Amcasertib in Multiple Tumor Types at ASCO 2017

CAMBRIDGE, Mass., May 18, 2017 /PRNewswire/ -- Boston Biomedical, Inc., an industry leader in the development of next-generation cancer therapeutics designed to inhibit cancer stemness pathways, today announced it will feature 11 clinical data poster presentations on investigational compounds evaluating napabucasin and amcasertib in nine different tumor types at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held from June 2-6, in Chicago. Read More

05/02/17

Featured in P&T Community: Napabucasin’s Potential for Treating Advanced Colorectal Cancer

P&T Community, a print and online publication that reports on drug forecasts and analysis for a target audience of pharmacy and therapeutic committee members, recently published an in-depth article in the April 2017 issue exploring investigational therapies in development for the treatment of advanced colorectal cancer (CRC). Read More

05/01/17

Featured in OncLive: Dr. O'Neil on Stemness Inhibitors for CRC Treatment

OncLive, an oncology-focused print and online trade media outlet, recently posted an interview with Bert O’Neil, M.D. about the emerging role of stemness inhibitors for the treatment of metastatic colorectal cancer (mCRC). Read More

04/04/17

Boston Biomedical Presents New Preclinical Data at AACR 2017 Highlighting the Potential Role of Cancer Stemness Inhibition

Boston Biomedical, an industry leader in the development of next-generation cancer therapeutics designed to inhibit cancer stemness pathways, presented preclinical data from its research and development portfolio at the 2017 American Association for Cancer Research (AACR) Annual Meeting held from April 1-5, in Washington, D.C. Read More

03/22/17

Boston Biomedical Celebrates 10-Year Anniversary of its Founding and Announces Appointment of Patricia S. Andrews as Chief Executive Officer

Boston Biomedical, an industry leader in the development of next-generation cancer therapeutics designed to target cancer stemness pathways, today announced its Board of Directors has appointed Patricia S. Andrews as Chief Executive Officer, effective April 24, 2017. Read More

03/09/17

Boston Biomedical to Present Preclinical Data on Targeting Cancer Stemness at AACR 2017

CAMBRIDGE, Mass. March 9, 2017 – Boston Biomedical, an industry leader in the development of next-generation cancer therapeutics designed to inhibit cancer stemness pathways, will present data from six preclinical studies – including five late-breaking posters – from its research and development portfolio at the upcoming 2017 American Association for Cancer Research (AACR) Annual Meeting held from April 1-5, in Washington, D.C. Read More

02/21/17

Boston Biomedical Initiates CanStem111P: A Global Phase 3 Study Investigating Cancer Stemness Inhibitor Napabucasin in Patients With Metastatic Pancreatic Cancer

Boston Biomedical, an industry leader in the development of next-generation cancer therapeutics designed to inhibit cancer stemness pathways, has initiated dosing of the first patient in a new global phase 3 study, CanStem111P. The study will investigate napabucasin – an orally administered, first-in-class, investigational agent designed to inhibit cancer stemness pathways by targeting STAT3 – in combination with standard of care (nab-paclitaxel plus gemcitabine) in patients with metastatic pancreatic cancer. Read More

01/21/17

Boston Biomedical Presents Clinical Data on First-in-Class Cancer Stemness Inhibitor Napabucasin at 2017 ASCO GI Symposium

CAMBRIDGE, Mass. January 21, 2017 – Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, today presented data from two clinical studies for its lead investigational compound, napabucasin, at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco. Read More

01/18/17

Boston Biomedical to Highlight Data for Cancer Stemness Inhibitor Napabucasin in Patients with Colorectal Cancer at 2017 ASCO GI

Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, will feature data from two clinical studies for its lead investigational compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, held from January 19-21, in San Francisco. Read More

11/04/16

Boston Biomedical to Highlight Data for Investigational WT1 Cancer Peptide Vaccine, DSP-7888, at ASH Annual Meeting & Exposition

Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, announced today that it will feature two data posters at the 2016 American Society of Hematology (ASH) Annual Meeting and Exposition, held from December 3 to 6, in San Diego. Read More

10/21/16

Boston Biomedical Initiates CanStem303C: A Global Phase III Study Investigating Cancer Stemness Inhibitor Napabucasin in Patients With Pretreated Advanced Colorectal Cancer

Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, today announced dosing of the first patient in CanStem303C, a new global Phase III study investigating napabucasin in combination with standard of care (FOLFIRI) in patients with previously treated metastatic colorectal carcinoma (mCRC). Read More

07/13/16

Boston Biomedical Announces Generic Name of BBI-503: Amcasertib

Boston Biomedical has announced its investigational cancer stem cell pathway inhibitor BBI-503 will now be referred to by the generic name amcasertib. Read More

06/23/16

Boston Biomedical Announces First Orphan Drug Designation for Napabucasin in Gastric/GEJ Cancer

Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, announced that its lead investigational compound, napabucasin, has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in the treatment of gastric cancer, including gastroesophageal junction (GEJ) cancer. Read More

06/09/16

Boston Biomedical provides update on the final data analysis of CCTG/AGITG CO.23 study: a phase III global colorectal cancer monotherapy trial

Boston Biomedical announced today that the final data analysis of CO.23 has been completed and the detailed results have been submitted for presentation at the ESMO 2016 Congress. Read More

06/08/16

Featured in Targeted Oncology: Napabucasin Shows Promise in Advanced Ovarian Cancer at ASCO 2016

The clinical data results of a Phase Ib/II study of napabucasin (BBI-608) in combination with weekly paclitaxel in platinum resistant ovarian cancer was recently presented at the 2016 ASCO Annual Meeting and featured in an article by Targeted Oncology on June 8. Read More

06/07/16

Boston Biomedical Featured Seven Clinical Posters on Cancer Stem Cell Pathway Inhibitors Napabucasin and Amcasertib in Multiple Cancer Types at ASCO 2016

Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stem cell (CSC) pathways, featured clinical data on investigational compounds napabucasin (BBI-608) and amcasertib (BBI-503) in multiple tumor types at the 2016 American Society of Clinical Oncology (ASCO) annual meeting held from June 3 to 7, in Chicago. Read More

05/18/16

Boston Biomedical Announces Clinical Data on First-in-Class Investigational Cancer Stem Cell Pathway Inhibitors Napabucasin and Amcasertib in Multiple Cancer Types at ASCO 2016

Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stem cell (CSC) pathways, will feature clinical data on investigational compounds napabucasin (BBI-608) and amcasertib (BBI-503) in multiple tumor types at the 2016 American Society of Clinical Oncology annual meeting, held from June 3 to June 7, in Chicago. Read More

03/17/16

Boston Biomedical to Unveil Preclinical Data Underscoring the Potential for Cancer Stem Cell Pathway Inhibition at AACR 2016

Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stem cell (CSC) pathways, will exhibit two preclinical data posters at the 2016 American Association for Cancer Research (AACR) Annual Meeting, held from April 16 to 20, in New Orleans, LA. Read More

02/25/16

Transpacific Collaboration Results in Boston Biomedical Feature in Japan

Following collaboration across the Pacific was an article recently published in Japan Times to highlight Boston Biomedical as Sumitomo Dainippon Pharma Co., Ltd. “gateway to ‘first-in-class’ innovation.” Read More

02/11/16

Featured in OncLive: First-in-Class Drug Targets Stem Cells in Gastric Cancer Trial

OncLive published an article highlighting napabucasin (BBI-608), the “most advanced new drug in clinical development designed specifically to attack cancer stem cells (CSCs),” by interviewing Manish A. Shah, MD, Director of Gastrointestinal Oncology at New York-Presbyterian/Weill Cornell Medical Center and Lead Investigator of the BRIGHTER study. Read More

01/25/16

Boston Biomedical's Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium

Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stem cell (CSC) pathways, announced that three poster presentations were highlighted at the 2016 Gastrointestinal Cancers Symposium, held by the American Society of Clinical Oncology (ASCO), January 21 to 23, 2016, in San Francisco. Read More

01/23/16

Media Calls Attention to Napabucasin Data at ASCO GI 2016

Boston Biomedical exhibited three posters involving studies of the “first-in-class cancer stemness inhibitor” napabucasin (BBI-608), at the 2016 Gastrointestinal Cancers Symposium, held by the American Society of Clinical Oncology (ASCO), January 21 to 23, 2016, in San Francisco. Read More

01/20/16

Boston Biomedical’s Investigational Cancer Stem Cell Pathway Inhibitor Napabucasin to be Highlighted at the ASCO 2016 Gastrointestinal Cancers Symposium

Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stem cell (CSC) pathways, announced today three abstracts to be presented at the 2016 Gastrointestinal Cancers Symposium, held by the American Society of Clinical Oncology (ASCO), January 21 to 23, 2016, in San Francisco. Read More

01/19/16

Boston Biomedical Announces Generic Name of BB608: Napabucasin

Boston Biomedical has announced its investigational cancer stem cell pathway inhibitor BB608 (also known as BBI608) will now be referred to under the generic name napabucasin. Currently under global Phase III development, orally-administered napabucasin is designed to inhibit cancer stem cell pathways by specifically targeting STAT3. Read More

12/01/15

Biotech Manufacturer’s PubHub Features Scientific Paper by Boston Biomedical

Biotechnology manufacturer, Promega Corporation, featured a scientific paper authored by Boston Biomedical in a recent post, suggesting “cancer stemness… may hold the key to identifying the most powerful and effective target drugs for halting their metastatic capabilities.” Read More

11/11/15

Media Calls Napabucasin Potential Novel Cancer Stemness Inhibitor in Research

OncLive published an article by Jane de Lartigue, PhD, on the history of cancer stem cells (CSCs), or a group of cells with stem cell–like properties within the heterogeneous makeup of a tumor. Read More

08/05/15

Nobel Laureate Dr. James Watson, Co-discoverer of the DNA Double Helix, Becomes an Advisor to Boston Biomedical

James D. Watson, co-discoverer of the DNA double helix, has been appointed as an advisor to Boston Biomedical. Dr. Watson is a past winner of the Nobel Prize in Physiology or Medicine, and currently serves as Chancellor Emeritus at Cold Springs Harbor Laboratory in New York. Read More

06/01/15

Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types

Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stem cell (CSC) pathways, will present clinical data today on the investigational compounds BBI608 and BBI503 in multiple tumor types at the 2015 American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Read More

05/13/15

Boston Biomedical to Highlight Data Examining Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types at ASCO 2015

Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stem cell (CSC) pathways, will present clinical data on the investigational compounds BBI608 and BBI503 in multiple tumor types at the 2015 American Society of Clinical Oncology annual meeting, held from May 29 to June 2, 2015, in Chicago, IL. Read More

04/28/15

Boston Biomedical to Present Data on First-in-Class Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 at ASCO 2015

Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stem cell (CSC) pathways, will present data on the investigational compounds BBI608 and BBI503 at the 2015 American Society of Clinical Oncology annual meeting, held from May 29 to June 2, 2015, in Chicago, IL. Read More

04/15/15

Boston Biomedical to Present Data on a First-in-Class Cancer Stem Cell Pathway Inhibitor BBI608 at AACR 2015

Cambridge, Mass. April 17, 2015 – Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stem cell (CSC) pathways, will present data on the investigational compound BBI608 at the 2015 American Association for Cancer Research (AACR) annual meeting, held from April 18 to 22, 2015, in Philadelphia, PA. Read More

04/08/15

Nobel Laureate Dr. James Watson, co-discoverer of the DNA double helix, visits Boston Biomedical

Cambridge, Mass – James D. Watson, co-discoverer of the DNA double helix, winner of the Nobel Prize in Physiology or Medicine, Chancellor Emeritus at Cold Springs Harbor Laboratory in New York, visited Boston Biomedical’s headquarters and R&D facilities in Cambridge, Massachusetts on March 26th. Read More

04/07/15

Pat Andrews, CCO, Featured in “Women in Pharma” Initiative

Featured in eyeforpharma is Boston Biomedical’s Chief Commercial Officer (CCO) and Executive Vice President (EVP), Pat Andrews. Published for the outlet’s initiative, “Women in Pharma,” which profiles leading women in the industry, the article chronicles Andrews’ experience in corporate finance before following her desire to contribute to greater advancements in the health industry, which she calls, “the common good.” Read More

01/16/15

“Top Women in Pharma and Healthcare” Include Pat Andrews, CCO

PM360 nominated and interviewed Boston Biomedical’s Chief Commercial Officer (CCO) and Executive Vice President (EVP), Pat Andrews, as one of six “Top Women in Pharma and Healthcare.” Read More

06/19/14

Sumitomo Dainippon Pharma announces Change of the Company’s English trade name

Sumitomo Dainippon Pharma Co., Ltd. announced today that it has changed the Company’s English trade name following the approval of the partial amendment to its articles of incorporation at the 194th Annual Shareholders’ Meeting. Read More

06/16/14

Boston Biomedical Announces Clinical Data Presentation Of Its Cancer Stem Cell Inhibitor Programs

Boston Biomedical provided a summary of the clinical data presented at the 2014 American Society of Clinical Oncology (ASCO) 50th annual meeting, held from May 30 to June 3, 2014, in Chicago, IL. Read More

05/23/14

Boston Biomedical provides an update on its CO.23 study: a Phase III global colorectal cancer monotherapy trial

Boston Biomedical announced today that the protocol-defined first interim analysis of the initial 96 patients enrolled into its CO.23 study has been completed. Read More

02/18/14

Ambassador Sun Guoxiang Visits Boston Biomedical

Ambassador Sun Guoxiang, Consul General of the People's Republic of China in New York, visited Boston Biomedical’s headquarters and state-of-the-art R&D facilities in Cambridge, Massachusetts. Read More

11/14/13

Boston Biomedical Appoints Patricia S. Andrews as Chief Commercial Officer

Boston Biomedical announced that it has appointed Patricia S. Andrews as Executive Vice President and Chief Commercial Officer as it begins strategic planning and preparations for the commercialization of its cancer stem cell inhibitors with its lead asset, BBI608, currently in a global Phase 3 clinical trial for metastatic colorectal cancer. Read More

08/26/13

Yahoo Finance: MassEcon Announces Finalists for Its Tenth Annual Team Massachusetts Economic Impact Awards

Finalists Selected Based on Job Growth, Investment, and Facility Expansion. Read More

07/09/13

Boston Biomedical announces the Grand Opening of its Cambridge Headquarters

For drug maker Boston Biomedical, the third time was the charm. Read More

07/09/13

Boston.com: Boston Biomedical hosts long-delayed opening of its new headquarters on Memorial Drive

For drug maker Boston Biomedical, the third time was the charm. Read More

05/13/13

Video interview with Dr. Chiang Li of Boston Biomedical, Inc.

Dr. Chiang Li is interviewed on The Immigrant Learning Center, Inc.’s YouTube channel. Read More

05/10/13

Boston.com: Immigrant entrepreneurs honored for their economic, social, and scientific contributions

Dr. Chiang Li is honored with the Outstanding Science/Technology Business Award at The Immigrant Learning Center, Inc.’s 2013 Immigrant Entrepreneur Awards Dinner. Read More

02/11/13

Dr. Chiang J. Li interviewed on WBZ Radio

Boston Biomedical President and CEO Chiang J. Li is interviewed by WBZ's Anthony Silva about the company's new Cambridge headquarters. Read More

02/08/13

Boston Globe: Boston.com: Snow forecast cancels ribbon-cutting for Boston Biomedical and the Dainippon Sumitomo Pharma Global Oncology Center in Cambridge

Friday was supposed to have been a big day for Boston Biomedical. The cancer-drug company is looking to double its headcount from 50 to 100 by the end of the year, and it was all set to celebrate its relocation from Norwood to a much larger space in Cambridge. Read More

02/08/13

Boston Herald: Boston Biomedical ribbon cutting postponed

A planned ribbon cutting today to celebrate the grand opening of Boston Biomedical’s new Cambridge headquarters has been rescheduled because of the snowstorm. Read More

02/07/13

Boston Business Journal: Mass High Tech Bioflash: Boston Biomedical moves to Cambridge, expands sixfold

Six years after founding Boston Biomedical Inc. as a way to employ 26 researchers being laid off from ArQule Inc. (Nasdaq: ARQL), Chiang J. Li is moving the company into much bigger offices in Cambridge, Mass. and plans to have 100 employees by the end of the year. Read More

09/03/12

Fierce Biotech: BBI608 named in Top 10 Late-Stage Cancer Drugs of 2012

An emerging area in cancer drug development has been treatments that target cancer stem cells (CSC), upstarts that can duck an attack from chemotherapy and evolve into tumor cells. Japan-based drugmaker Dainippon Sumitomo put itself at the front of the race to develop CSC-targeted drugs with its buyout of Boston Biomedical, which is gearing up for a late-stage study of BBI608 for treating colorectal cancer. Read More

08/20/12

Dainippon Sumitomo Pharma announces organizational changes: Establishment of the "DSP Cancer Institute"

Osaka, Japan, August 20, 2012 - Dainippon Sumitomo Pharma Co., Ltd. (DSP) (Headquarters: Osaka, Japan; President: Masayo Tada) announces today that it will establish a new organization specializing in the oncology area called the "DSP Cancer Institute". Read More

04/02/12

Drug Discovery News: The Little Biotech that could

Dr. Chiang Li is not the kind of guy you’d expect to be living on a minimum-wage salary. A graduate of the Harvard-MIT Division of Health Science and Technology and Harvard Medical School, he completed his residency and fellowship at Brigham & Women’s Hospital/Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center before moving on to found or co-found Cyclis Pharma and Cequent Pharma, both of which were later acquired, and ArQule Oncology. Read More

04/02/12

Drug Discovery News: Pharma pink slippers find pot of gold

Just a few years after rising from the ashes of a pharma company “restructuring,” Boston Biomedical, a private biotechnology company with a clinical-stage product pipeline targeting cancer stem cells (CSCs), has been acquired by top Japanese pharma Dainippon Sumitomo Pharma Co. Ltd. (DSP) for as much as $2.63 billion. Read More

03/19/12

BioCentury: Boston Biomedical: Quick path to takeout by Dainippon for cancer stem cell tech - Incentivized Success

Boston Biomedical's story shows what can happen when researchers are given the imperative and the resources to invent as if their livelihoods depend on it. The company emerged from ArQule Inc. in 2006 and in six years has generated a Phase III-ready cancer stem cell program that fetched a $200 million acquisition offer from Dainippon Sumitomo Pharma Co. Ltd. Read More

03/02/12

CBS: Boston Biomedical being sold to Japanese competitor

A five-year-old local biotech will be getting a $200 million upfront payment as part of its sale to a large Japanese drug company. Read More

02/29/12

The Wall Street Journal Market Watch: Dainippon Sumitomo Pharma to buy Boston Biomedical

Dainippon Sumitomo Pharma Co. said Wednesday it has agreed to buy Boston Biomedical Inc., an unlisted U.S. venture specializing in cancer treatments, in a deal valued at $200 million. Read More

02/29/12

Boston Herald: Japanese co. to buy Boston Biomedical

The Norwood company will be sold to Dainippon Sumitomo Pharma Co., the same company that scooped up Marlboro-based Sepracor for $2.6 billion in 2009. Read More

02/29/12

Boston Business Journal: Japanese Pharma to buy Boston Biomedical

Japanese drug maker Dainippon Sumitomo Pharma Co. has agreed to buy Boston Biomedical, a privately held biotechnology company, for $200 million in upfront payments, plus a potential for an additional $540 million in development milestone payments, and a potential $1.89 billion in sales milestone payments. Read More

12/03/09

Next Generation RNAi Technology Discovered by AiRNA Pharmaceuticals and Boston Biomedical Published in Nature Biotechnology

NORWOOD, Mass, [December 3rd] -- AiRNA Pharmaceuticals, Inc., a RNAi therapeutics company based on next generation proprietary RNAi technologies, and Boston Biomedical, Inc., a biotechnology company developing novel therapies targeting cancer stem cells, today announced that asymmetrical interfering RNA (aiRNA), a new fundamental RNAi technology discovered by the companies, is being published in the December issue of Nature Biotechnology. Read More

02/16/07

ArQule Discovery Arm Carries on as Boston Biomedical

Dr. Chiang Li could see the writing on the wall. As chief scientific officer at ArQule Inc. in Woburn, he was aware of the Darwinist nature of biotechnology companies. Read More

01/29/07

ArQule spins out Boston Biomedical with $5M research deal

Mass High Tech: The Journal of New England Technology - January 29, 2007 Woburn-based biotechnology firm ArQule Inc.'s former chief scientific officer Chiang Li has formed a new drug research firm, Boston Biomedical Inc., with a $5 million research contract from his former employer, for which he plans to remain chairman of the scientific advisory board, officials said. Read More

Join Our Team

We are looking for motivated, passionate and skilled scientists and commercial team members.

Learn More